JP2008526939A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526939A5
JP2008526939A5 JP2007550844A JP2007550844A JP2008526939A5 JP 2008526939 A5 JP2008526939 A5 JP 2008526939A5 JP 2007550844 A JP2007550844 A JP 2007550844A JP 2007550844 A JP2007550844 A JP 2007550844A JP 2008526939 A5 JP2008526939 A5 JP 2008526939A5
Authority
JP
Japan
Prior art keywords
composition
tetanus toxoid
use according
serogroup
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007550844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526939A (ja
JP5687405B2 (ja
Filing date
Publication date
Priority claimed from GBGB0500787.7A external-priority patent/GB0500787D0/en
Application filed filed Critical
Publication of JP2008526939A publication Critical patent/JP2008526939A/ja
Publication of JP2008526939A5 publication Critical patent/JP2008526939A5/ja
Application granted granted Critical
Publication of JP5687405B2 publication Critical patent/JP5687405B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007550844A 2005-01-14 2006-01-13 髄膜炎菌結合体ワクチン接種 Expired - Lifetime JP5687405B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0500787.7 2005-01-14
GBGB0500787.7A GB0500787D0 (en) 2005-01-14 2005-01-14 Integration of meningococcal conjugate vaccination
PCT/GB2006/000120 WO2006075170A1 (en) 2005-01-14 2006-01-13 Meningococcal conjugate vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012128887A Division JP2012162580A (ja) 2005-01-14 2012-06-06 髄膜炎菌結合体ワクチン接種

Publications (3)

Publication Number Publication Date
JP2008526939A JP2008526939A (ja) 2008-07-24
JP2008526939A5 true JP2008526939A5 (enExample) 2009-01-08
JP5687405B2 JP5687405B2 (ja) 2015-03-18

Family

ID=34224621

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007550844A Expired - Lifetime JP5687405B2 (ja) 2005-01-14 2006-01-13 髄膜炎菌結合体ワクチン接種
JP2012128887A Withdrawn JP2012162580A (ja) 2005-01-14 2012-06-06 髄膜炎菌結合体ワクチン接種
JP2014104349A Withdrawn JP2014144984A (ja) 2005-01-14 2014-05-20 髄膜炎菌結合体ワクチン接種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012128887A Withdrawn JP2012162580A (ja) 2005-01-14 2012-06-06 髄膜炎菌結合体ワクチン接種
JP2014104349A Withdrawn JP2014144984A (ja) 2005-01-14 2014-05-20 髄膜炎菌結合体ワクチン接種

Country Status (20)

Country Link
US (1) US8529908B2 (enExample)
EP (2) EP2193810A1 (enExample)
JP (3) JP5687405B2 (enExample)
CN (2) CN101163508A (enExample)
AT (1) ATE463261T1 (enExample)
AU (1) AU2006205656B2 (enExample)
BR (1) BRPI0606523A2 (enExample)
CA (1) CA2595128C (enExample)
CY (1) CY1110140T1 (enExample)
DE (1) DE602006013406D1 (enExample)
DK (1) DK1835939T3 (enExample)
ES (1) ES2343855T3 (enExample)
GB (1) GB0500787D0 (enExample)
MX (1) MX2007008537A (enExample)
NZ (1) NZ560201A (enExample)
PL (1) PL1835939T3 (enExample)
PT (1) PT1835939E (enExample)
RU (1) RU2429011C2 (enExample)
SI (1) SI1835939T1 (enExample)
WO (1) WO2006075170A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12302A (en) * 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
EP2957300B1 (en) 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20080305127A1 (en) * 2005-12-23 2008-12-11 Glaxosmithkline Biologicals S.A. Conjugate Vaccines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
ES2555786T3 (es) * 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
WO2012163289A1 (zh) 2011-06-01 2012-12-06 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
BR112015014250A2 (pt) * 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa método para imunizar um bebê, vacina de combinação e, kit
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2019003238A1 (en) * 2017-06-27 2019-01-03 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. NOVEL MULTIVALENT VACCINE COMPOSITION CONTAINING POLYSACCHARIDE - PROTEIN CONJUGATES AND FORMULATION THEREOF
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323103A (en) 1928-12-07 1929-12-24 Fred Cunningham Firth Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US4965388A (en) 1990-01-02 1990-10-23 Dow Corning Corporation Method for preparing organohalosilanes
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
CA2142981C (en) 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
IL122588A (en) 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
OA12302A (en) 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
EP2957300B1 (en) 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011248A (es) 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
JP2006528936A (ja) 2003-05-07 2006-12-28 アヴェンティス パストゥール インコーポレイテッド 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン
BRPI0410423A (pt) 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
JP2007516181A (ja) 2003-06-23 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌血清群aおよびcに対する免疫方法
AU2004281630A1 (en) 2003-08-06 2005-04-28 Bio-Manguinhos/Fiocruz Process for preparing polysaccharide-protein conjugate vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
SI1740217T1 (sl) * 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US20080305127A1 (en) 2005-12-23 2008-12-11 Glaxosmithkline Biologicals S.A. Conjugate Vaccines

Similar Documents

Publication Publication Date Title
JP2008526939A5 (enExample)
JP2007535527A5 (enExample)
JP2009525260A5 (enExample)
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
Khatun et al. An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity
JP2011042693A5 (enExample)
CN101785857B (zh) 一种新的肺炎球菌结合疫苗及其制备方法
RU2007130774A (ru) Вакцинация менингококковыми конъюгатами
HK1214129A1 (zh) 用於缀合疫苗的经过修饰的多糖
HU228384B1 (en) Vaccine compositions
US9956278B2 (en) Multivalent meningococcal conjugates and methods for preparing conjugates
JP2007516219A5 (enExample)
EP2172213A3 (en) Injectable vaccines against multiple meningococcal serogroups
JP2022068303A (ja) 多価肺炎球菌多糖体-タンパク質複合体組成物
TW201718005A (zh) 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
RU2008112289A (ru) Множественная вакцинация, включающая менингококки серогруппы с
RU2006142158A (ru) Вакцинация менингококковыми конъюгатами
JP2004501873A5 (enExample)
JP2007507487A5 (enExample)
BR112020014978A2 (pt) Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
JP2008543907A5 (enExample)
JP2007507578A5 (enExample)
JP2014218516A5 (enExample)
HUP0302999A2 (hu) Multivalens, meningokokkusz-eredetû poliszaccharid és fehérje konjugátumát tartalmazó vakcina
JP2008543905A5 (enExample)